ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
09 Apr, 2025
A research team from Helmholtz Munich and the Technical University of Munich has developed an advanced delivery system, ENVLPE, designed to transport CRISPR/Cas9-based gene-editing tools into living cells with greater efficiency. The system uses engineered, non-infectious virus-like particles (VLPs) to precisely correct defective genes, demonstrated successfully in mouse models of inherited blindness. ENVLPE also holds promise for advancing cancer therapies by enabling genetic manipulation of immune cells, making them more universally compatible and accessible for a broader range of patients. The technology addresses critical limitations of previous delivery systems, such as inefficient packaging and instability, offering a more effective and safer approach for gene-editing applications. The team is now focused on further improving the system for clinical use and exploring its potential in targeted therapies for various diseases.